Objective To provide updated guidelines for pharmacologic management of juvenile
idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) …

Objective To examine the safety and efficacy of the interleukin‐1 (IL‐1) receptor antagonist
anakinra as first‐line therapy for systemic juvenile idiopathic arthritis (JIA). Methods Patients …

Objective To assess the benefit of the recombinant human interleukin‐1 receptor antagonist
anakinra in treating pediatric patients with secondary hemophagocytic lymphohistiocytosis ( …

Objective To provide recommendations for the management of juvenile idiopathic arthritis (JIA)
with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and …

Objective Opioid prescribing recently has come under intense scrutiny. However, longitudinal
patterns of prescription opioid receipt in a population‐based cohort of patients with chronic …

Importance Active pediatric COVID-19 pneumonia and MIS-C are two disease processes
requiring rapid diagnosis and different treatment protocols. Objective To distinguish active …

Background SARS-CoV-2 has been found to be exquisitely adept at triggering
autoimmunity and multiple new onset autoimmune diseases have been described as a post-infectious …

Objective To compare incidence rates of selected opportunistic infections among children
with and children without juvenile idiopathic arthritis (JIA). Methods Using US national …

Objective Systemic juvenile idiopathic arthritis–associated lung disease (SJIA‐LD) is a life‐threatening
disease complication. Key questions remain regarding clinical course and …

Objective To determine whether tumour necrosis factor inhibitor (TNFi) use is associated
with an increased rate of incident malignancy compared with no TNFi use in the treatment of …